argenx SE Investor Day Presentation Deck
Today's Agenda
Advancing Towards argenx 2025 | Tim Van Hauwermeiren, Chief Executive Officer and Co-Founder
Efgartigimod: Differentiation of our Anti-FcRn Fc Fragment | Hans de Haard, Chief Scientific Officer and Co-Founder
Fifth Efgartigimod Indication: Myositis | Bas van der Woning, Research Fellow
Sixth Efgartigimod Indication: Bullous Pemphigoid | Peter Verheesen, Research Fellow
KOL Panel: Myositis and Bullous Pemphigoid | Moderated by Albert Kovera, Global Marketing
Rohit Aggarwal, MD, MS, University of Pittsburgh Medical Center
Russell Hall, MD, Duke University Medical Center
ā
ā
ARGX-117 Phase 1 Data | New Biology Insights for Multifocal Motor Neuropathy
Olivier Van de Steen, Medical Director | Inge Van de Walle, Principal Scientist
Q+A
argenx
4View entire presentation